(4-Oxo-3-phenylchromen-7-yl) propanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: (4-Oxo-3-phenylchromen-7-yl) propanoate
• 化学式: C₁₈H₁₄O₄
• 分子量: 294.3
• InChiKey: CZTAIVOACKUJQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• CONJUGATED SMALL MOLECULES
  申请人：Grotzfeld Robert M.

  公开号：US20100048890A1

  公开（公告）日：2010-02-25

  Provided herein are linker compounds and conjugates that include the linker compounds. In one embodiment, the linker compounds comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compounds are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanalytical applications. In particular, the biopharmaceutically useful compounds are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications.

  本文提供了链接剂化合物和包括该链接剂化合物的共轭物。在一种实施例中，该链接剂化合物包括2或3个6-氨基己酸残基和可选的7-10个聚乙二醇（PEG）残基。该链接剂化合物有用于与在生物制药或生物分析应用中有用的一个或多个组分形成共轭物。特别是，生物制药上有用的化合物是激酶抑制剂。本文所描述的共轭物在各种诊断、分离和治疗应用中具有实用性。
• NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE
  申请人：Smith Jeffrey W.

  公开号：US20100305121A1

  公开（公告）日：2010-12-02

  The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.